Fig. 1

Subgroup analysis of the effect of eplerenone versus placebo on HF-related outcomes across diabetes and kidney disease categories. *CKD included eGFR at baseline < 45 ml/min/1.73 m² or UACR at baseline > 30 mg/g. HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; UACR, urine albumin creatinine ratio